Author Archives: William Looney
By William Looney | Published: February 15, 2012
As the hurdles to successful commercialization of new medicines continue to mount, the ability to find and exploit cost efficiencies in the development process has become a critical source of competitive advantage. This is true not only for biologic drugs but also increasingly for vaccines, now a high growth segment of the medicines business, with [...]
By William Looney | Published: February 9, 2012
Medical Economics has been named "Media Brand of the Year" but MM&M magazie, one of sister publication Pharm Exec's main competitors.
By William Looney | Published: February 3, 2012
The Healthcare Businesswomen’s Association (HBA) has announced that its 2012 Woman of the Year (WOTY) is Carolyn Buck Luce, global pharmaceutical sector leader at Ernst & Young. She will be honored at the HBA’s annual Woman of the Year luncheon on May 3 in New York – the 23rd recipient from an organization that has set the pace in [...]
By William Looney | Published: February 1, 2012
William Looney looks at the three P’s of effectiveness research: PCORI, Priorities, and Politics If you ever wanted to know what health economists might do with a billion dollars, the Obama Administration’s Patient-Centered Outcomes Research Institute [PCORI] is about to tell all: not right down to the penny, but good enough. The congressionally funded – [...]
By William Looney | Published: January 11, 2012
Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues, because if you cannot justify your costs how do you expect to prevail on price?